• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

增殖指数（Ki67）在乳腺导管癌预测中的应用

Proliferative Index (Ki67) for Prediction in Breast Duct Carcinomas.

作者信息

Ahmed Shatha Th, Ahmed Azad M, Musa Dildar H, Sulayvani Farhad K, Al-Khyatt Muzahm, Pity Intisar S

机构信息

MBChB, Msc, PhD mol. Pathology/UK, College of Medicine,Ninevah University, Iraq. Email:

出版信息

Asian Pac J Cancer Prev. 2018 Apr 25;19(4):955-959. doi: 10.22034/APJCP.2018.19.4.955.

DOI:10.22034/APJCP.2018.19.4.955
PMID:29693354
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6031788/
Abstract

Background and objectives: To date, many tumor markers have been used to predict prognosis and therapeutic response in patients with breast cancer. The well established and routinely applied tumor markers are the estrogen-receptor, progesterone-receptor and Her2/neu-receptor. In the current study, we aimed to highlight any association of the proliferation index (Ki67) in breast infiltrative duct carcinoma with the tumor grade, tumor size and nodal status in addition to hormone receptor status. Tissue sections were stained immunohistochemically for Ki67 nuclear antigen, estrogen, progesterone and Her2/neu receptors using an automated Dako machine (Dako Denmark. There was a significant inverse relationship of Ki67 levels with ER and PR, while values were directly proportional to the tumor grade and Her2/neu status. No significant association was found between Ki67 and size of tumor or nodal status. Ki67 immunoexpression may offer an independent predictive tumor marker and for routine application in cases of breast cancer.

摘要

背景与目的

迄今为止，许多肿瘤标志物已被用于预测乳腺癌患者的预后和治疗反应。已确立且常规应用的肿瘤标志物是雌激素受体、孕激素受体和Her2/neu受体。在本研究中，我们旨在强调乳腺浸润性导管癌中增殖指数（Ki67）除了与激素受体状态外，还与肿瘤分级、肿瘤大小和淋巴结状态之间的任何关联。使用自动达科仪（丹麦达科公司）对组织切片进行免疫组织化学染色，检测Ki67核抗原、雌激素、孕激素和Her2/neu受体。Ki67水平与雌激素受体（ER）和孕激素受体（PR）呈显著负相关，而与肿瘤分级和Her2/neu状态呈正比。未发现Ki67与肿瘤大小或淋巴结状态之间存在显著关联。Ki67免疫表达可能提供一种独立的预测性肿瘤标志物，可用于乳腺癌病例的常规应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04c2/6031788/0ce031c8d603/APJCP-19-955-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04c2/6031788/9912f8372493/APJCP-19-955-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04c2/6031788/5c1a03c2e48a/APJCP-19-955-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04c2/6031788/98cd5f5df353/APJCP-19-955-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04c2/6031788/4b9917b4dce7/APJCP-19-955-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04c2/6031788/0ce031c8d603/APJCP-19-955-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04c2/6031788/9912f8372493/APJCP-19-955-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04c2/6031788/5c1a03c2e48a/APJCP-19-955-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04c2/6031788/98cd5f5df353/APJCP-19-955-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04c2/6031788/4b9917b4dce7/APJCP-19-955-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04c2/6031788/0ce031c8d603/APJCP-19-955-g005.jpg

相似文献

1
Proliferative Index (Ki67) for Prediction in Breast Duct Carcinomas.增殖指数（Ki67）在乳腺导管癌预测中的应用
Asian Pac J Cancer Prev. 2018 Apr 25;19(4):955-959. doi: 10.22034/APJCP.2018.19.4.955.
2
Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients.乳腺癌中的Ki67指数：与其他预后标志物的相关性及在巴基斯坦患者中的潜力
Asian Pac J Cancer Prev. 2013;14(7):4353-8. doi: 10.7314/apjcp.2013.14.7.4353.
3
Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.浸润性导管癌患者中Ki-67、雌激素受体（ER）、孕激素受体（PR）、人表皮生长因子受体2/neu（Her2/neu）、p21、表皮生长因子受体（EGFR）和拓扑异构酶II-α（TOP II-α）表达之间的关系及其与预后的相关性。
Asian Pac J Cancer Prev. 2015;16(2):823-9. doi: 10.7314/apjcp.2015.16.2.823.
4
Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.乳腺癌中Ki67的表达。沙特患者中与预后标志物及临床病理参数的相关性
Saudi Med J. 2016 Feb;37(2):137-41. doi: 10.15537/smj.2016.2.12285.
5
Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.无腋窝淋巴结转移乳腺癌的Ki67增殖指数及其与无病生存期的关系
Asian Pac J Cancer Prev. 2016;17(3):1347-50. doi: 10.7314/apjcp.2016.17.3.1347.
6
High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.Ki67/BCL2 高指数与早期乳腺癌的不良预后相关。
Postgrad Med J. 2016 Dec;92(1094):707-714. doi: 10.1136/postgradmedj-2015-133531. Epub 2016 May 24.
7
Ki-67 is a prognostic marker for hormone receptor positive tumors.Ki-67是激素受体阳性肿瘤的一个预后标志物。
Clin Transl Oncol. 2016 Oct;18(10):996-1002. doi: 10.1007/s12094-015-1472-y. Epub 2016 Jan 7.
8
Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers.Geminin表达水平在雌激素受体阳性且人表皮生长因子受体2阴性乳腺癌的高Ki67亚组中的预后意义
Breast Cancer. 2016 Mar;23(2):224-30. doi: 10.1007/s12282-014-0556-9. Epub 2014 Aug 1.
9
Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.PgR表达作为通过Ki67标记指数分类的中度风险ER阳性/HER2阴性乳腺癌患者预后因素的作用。
BMC Cancer. 2017 May 22;17(1):354. doi: 10.1186/s12885-017-3331-4.
10
Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.孕激素受体表达在雌激素受体阳性、人表皮生长因子受体2阴性、淋巴结阴性且Ki-67标记指数低的浸润性乳腺癌中的预后意义
Clin Breast Cancer. 2017 Feb;17(1):41-47. doi: 10.1016/j.clbc.2016.06.012. Epub 2016 Jun 25.

引用本文的文献

1
Proliferative Markers in Breast Cancer and Chemotherapy Implications: A Comprehensive Review.乳腺癌中的增殖标志物及其化疗意义：综述
Health Sci Rep. 2025 Apr 8;8(4):e70626. doi: 10.1002/hsr2.70626. eCollection 2025 Apr.
2
The 1000 Mitoses Project: A Consensus-Based International Collaborative Study on Mitotic Figures Classification.《1000 有丝分裂项目：基于共识的国际有丝分裂图分类协作研究》
Int J Surg Pathol. 2024 Dec;32(8):1449-1458. doi: 10.1177/10668969241234321. Epub 2024 Apr 16.
3
The Role of miRNAs in the Prognosis of Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.

本文引用的文献

1
Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast.乳腺癌中雌激素和孕激素受体的免疫组织化学测定：与科特迪瓦302例患者临床病理因素的关系
BMC Cancer. 2017 Feb 7;17(1):115. doi: 10.1186/s12885-017-3105-z.
2
The correlation between Ki-67 with other prognostic factors in breast cancer: A study in Iranian patients.乳腺癌中Ki-67与其他预后因素的相关性：一项针对伊朗患者的研究。
Indian J Med Paediatr Oncol. 2016 Apr-Jun;37(2):95-9. doi: 10.4103/0971-5851.180136.
3
Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population.
微小RNA在三阴性乳腺癌预后中的作用：一项系统评价和荟萃分析
Diagnostics (Basel). 2022 Dec 30;13(1):127. doi: 10.3390/diagnostics13010127.
4
Arterial Spin Labeling Perfusion in Determining the IDH1 Status and Ki-67 Index in Brain Gliomas.动脉自旋标记灌注成像在确定脑胶质瘤异柠檬酸脱氢酶1（IDH1）状态及Ki-67指数中的应用
Diagnostics (Basel). 2022 Jun 12;12(6):1444. doi: 10.3390/diagnostics12061444.
5
Epigenetic alterations at distal enhancers are linked to proliferation in human breast cancer.远端增强子处的表观遗传改变与人类乳腺癌的增殖相关。
NAR Cancer. 2022 Mar 24;4(1):zcac008. doi: 10.1093/narcan/zcac008. eCollection 2022 Mar.
6
Fatty acid synthetase expression in triple-negative breast cancer.三阴性乳腺癌中脂肪酸合成酶的表达
J Pathol Transl Med. 2022 Mar;56(2):73-80. doi: 10.4132/jptm.2021.10.27. Epub 2022 Jan 21.
7
Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.乳腺癌中 BRCA1 蛋白、ER、PR 和 Her2/neu 的免疫组织化学表达：一项临床病理研究。
Asian Pac J Cancer Prev. 2020 Apr 1;21(4):1025-1029. doi: 10.31557/APJCP.2020.21.4.1025.
乳腺癌分子亚型及Ki67表达对中国人群新辅助化疗疗效及预后预测的价值
Medicine (Baltimore). 2016 May;95(18):e3518. doi: 10.1097/MD.0000000000003518.
4
Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.乳腺癌中Ki67的表达。沙特患者中与预后标志物及临床病理参数的相关性
Saudi Med J. 2016 Feb;37(2):137-41. doi: 10.15537/smj.2016.2.12285.
5
Ki-67 Expression in CRC Lymph Node Metastasis Does Not Predict Survival.Ki-67在结直肠癌淋巴结转移中的表达不能预测生存率。
Biomed Res Int. 2015;2015:131685. doi: 10.1155/2015/131685. Epub 2015 Sep 13.
6
Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study.乳腺癌亚型中Ki67、HER2/neu、p53、雌激素受体（ER）和孕激素受体（PR）状态之间的相互关系及其与肿瘤分级和淋巴结受累的关联：回顾性观察分析研究
Medicine (Baltimore). 2015 Aug;94(32):e1359. doi: 10.1097/MD.0000000000001359.
7
Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.浸润性导管癌患者中Ki-67、雌激素受体（ER）、孕激素受体（PR）、人表皮生长因子受体2/neu（Her2/neu）、p21、表皮生长因子受体（EGFR）和拓扑异构酶II-α（TOP II-α）表达之间的关系及其与预后的相关性。
Asian Pac J Cancer Prev. 2015;16(2):823-9. doi: 10.7314/apjcp.2015.16.2.823.
8
Prognostic significance of Ki-67 index value at the primary breast tumor in recurrent breast cancer.原发性乳腺癌中Ki-67指数值在复发性乳腺癌中的预后意义。
Mol Clin Oncol. 2014 Nov;2(6):1062-1068. doi: 10.3892/mco.2014.400. Epub 2014 Aug 22.
9
Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study.Ki-67在腋窝淋巴结阳性乳腺癌患者中的预后价值：一项回顾性队列研究
PLoS One. 2014 Feb 3;9(2):e87264. doi: 10.1371/journal.pone.0087264. eCollection 2014.
10
Association between tumor size and immunohistochemical expression of Ki-67, p53 and BCL2 in a node-negative breast cancer population selected from a breast cancer screening program.在乳腺癌筛查项目中选择的无淋巴结转移乳腺癌人群中，肿瘤大小与 Ki-67、p53 和 BCL2 的免疫组化表达之间的关系。
Anticancer Res. 2014 Jan;34(1):269-73.